Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
LONG-TERM TREATMENT OF CHRONIC-SCHIZOPHRENIA WITH RISPERIDONE - AN OPEN-LABEL, MULTICENTER STUDY OF 386 PATIENTS
Autore:
MOLLER HJ; GAGIANO CA; ADDINGTON DE; VONKNORRING L; TORRESPLANK JF; GAUSSARES C;
Indirizzi:
PSYCHIAT CLIN,NUSSBAUMSTR 7 D-80336 MUNICH GERMANY UNIV MUNICH,DEPT PSYCHIAT D-80539 MUNICH GERMANY UNIV ORANGE FREE STATE,DEPT PSYCHIAT BLOEMFONTEIN SOUTH AFRICA FOOTHILLS PROV GEN HOSP CALGARY AB T2N 2T9 CANADA UNIV HOSP,DEPT PSYCHIAT UPPSALA SWEDEN HOSP CHARLES PERRENS BORDEAUX FRANCE
Titolo Testata:
International clinical psychopharmacology
fascicolo: 3, volume: 13, anno: 1998,
pagine: 99 - 106
SICI:
0268-1315(1998)13:3<99:LTOCWR>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEGATIVE SYNDROME SCALE; DOUBLE-BLIND; PARALLEL-GROUP; HALOPERIDOL; DRUGS; PHARMACOLOGY; SEROTONIN-S2; EFFICACY; PLACEBO; SAFETY;
Keywords:
SCHIZOPHRENIA; RISPERIDONE; POSITIVE AND NEGATIVE SYNDROME SCALE; EXTRAPYRAMIDAL SYMPTOMS; ANTIPSYCHOTIC AGENTS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
39
Recensione:
Indirizzi per estratti:
Citazione:
H.J. Moller et al., "LONG-TERM TREATMENT OF CHRONIC-SCHIZOPHRENIA WITH RISPERIDONE - AN OPEN-LABEL, MULTICENTER STUDY OF 386 PATIENTS", International clinical psychopharmacology, 13(3), 1998, pp. 99-106

Abstract

An open-label, multicentre study was conducted to assess the long-term efficacy and safety of risperidone in patients,vith chronic schizophrenia. Three hundred and eighty-six patients at 70 centres in 11 countries received risperidone (2-16 mg/day) for up to 57 weeks; 247 patients were treated for at least 1 year. All but 48 patients had been treated,vith antipsychotic agents before entering the trial. The mean (+/-SD) daily risperidone dose at endpoint was 8.6 +/- 4.4 mg. The mean total Positive and Negative Syndrome Scale (PANSS) scores were reduced significantly from 76.7 at baseline to 67.4 at endpoint (p < 0.001). Even though no patients had acutely exacerbated symptoms at the start of the trial, mean scores on each of the PANSS positive, negative, and general psychopathology subscales were significantly reduced during the first month of open treatment, and these mean scores continued to improve over the course of the trial. At endpoint, 64% of patients were rated as improved on the Clinical Global Impression change scale. Extrapyramidal symptoms (scores on the Extrapyramidal Symptom Rating Scale) tended to decrease in severity or remained unchanged over the courseof risperidone treatment; 27.7% of patients required antiparkinsonianmedication during the study. The results demonstrate that risperidone's efficacy against the positive and negative symptoms of chronic schizophrenia can be maintained in long-term treatment with a low incidence of adverse experiences; moreover, the drug reduces preexisting extrapyramidal symptoms over time. Int Clin Psychopharmacol 13:99-106 (C) 1998 Lippincott-Raven Publishers.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 10:27:04